miRNA调控乳腺癌多药耐药机制的研究进展  

Advances in research on miRNA regulation of multidrug resistance in breast cancer

作　　者：邹翔[1] 王广泽 曲中原[3] 张月[1] ZOU Xiang;WANG Guangze;QU Zhongyuan;ZHANG Yue(Engineering Research Center of Natural Anticancer Drugs,Ministry of Education,Harbin University of Commerce,Harbin 150076,China;Post Doctoral Research Center of material Medica,Harbin University of Commerce,Harbin 150076,China;College of Pharmacy,Harbin University of Commerce,Harbin 150076,China)

机构地区：[1]哈尔滨商业大学国家教育部抗肿瘤天然药物工程研究中心,黑龙江哈尔滨150076 [2]哈尔滨商业大学药物研究所博士后科研工作站,黑龙江哈尔滨150076 [3]哈尔滨商业大学药学院,黑龙江哈尔滨150076

出　　处：《药物评价研究》2018年第10期1900-1905,共6页Drug Evaluation Research

基　　金：黑龙江省普通本科高等学校青年创新人才培养计划(UNPYSCT-2015070);国家自然科学基金青年基金项目(81102858);黑龙江省博士后科研启动金资助项目(LBH-Q16130);哈尔滨商业大学一般项目(17XN062);哈尔滨商业大学研究生创新科研项目(YJSCX2017-457HSD)

摘　　要：乳腺癌是女性发病率最高的恶性肿瘤之一。化学治疗是乳腺癌临床治疗的主要手段之一,然而乳腺癌细胞对化疗药物产生的MDR成为乳腺癌治疗的瓶颈。miRNA是一种存在于真核生物中的内源性非编码短链RNA,广泛参与到增殖、凋亡等多种生理过程。近年来,有关miRNA在乳腺癌MDR中的作用及机制研究取得了诸多进展,因此就miRNA调控乳腺癌MDR分子机制的研究进展做一综述。Breast cancer is one of the highest incidence of malignant tumors in women. Chemotherapy is one of the major methods for the clinical treatment of breast cancer. However, the MDR of breast cancer cells to chemotherapy drugs has become a bottleneck in the treatment of breast cancer. miRNAs are short endogenous noncoding RNAs exist in eukaryotes and widely involved in various physiological processes such as proliferation and apoptosis. In recent years, many advances have been made in studies on the effects and mechanisms of miRNA in breast cancer MDR. This article reviews the research progress of miRNA regulation mechanisms on breast cancer MDR.

关 键 词：乳腺癌 多药耐药 MIRNA 机制 进展 

分 类 号：R967[医药卫生—药理学]